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Abstract
Background: Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the
disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated
receptor gamma (PPARγ) modulator in vitro. Pharmacokinetic studies in mice showed that MH84 is bioavailable
after oral administration and reaches the brain. We recently demonstrated that MH84 improved mitochondrial
dysfunction in a cellular model of AD. In the present study, we extended the pharmacological characterization of
MH84 to 3-month-old Thy-1 AβPPSL mice (harboring the Swedish and London mutation in human amyloid
precursor protein (APP)) which are characterized by enhanced AβPP processing and cerebral mitochondrial
dysfunction, representing a mouse model of early AD.
Methods: Three-month-old Thy-1 AβPPSL mice received 12 mg/kg b.w. MH84 by oral gavage once a day for
21 days. Mitochondrial respiration was analyzed in isolated brain mitochondria, and mitochondrial membrane
potential and ATP levels were determined in dissociated brain cells. Citrate synthase (CS) activity was determined in
brain tissues and MitoTracker Green fluorescence was measured in HEK293-AβPPwt and HEK293-AβPPsw cells.
Soluble Aβ1–40 and Aβ1–42 levels were determined using ELISA. Western blot analysis and qRT-PCR were used to
measure protein and mRNA levels, respectively.
Results: MH84 reduced cerebral levels of the β-secretase-related C99 peptide and of Aβ40 levels. Mitochondrial
dysfunction was ameliorated by restoring complex IV (cytochrome-c oxidase) respiration, mitochondrial membrane
potential, and levels of ATP. Induction of PPARγ coactivator-1α (PGC-1α) mRNA and protein expression was
identified as a possible mode of action that leads to increased mitochondrial mass as indicated by enhanced CS
activity, OXPHOS levels, and MitoTracker Green fluorescence.
Conclusions: MH84 modulates β-secretase processing of APP and improves mitochondrial dysfunction by a PGC-
1α-dependent mechanism. Thus, MH84 seems to be a new promising therapeutic agent with approved in-vivo
activity for the treatment of AD.
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Background
Alzheimer’s disease (AD) is an age-related neurodegen-
erative disease and the primary cause for dementia in
the elderly which represents a growing public health
issue [1]. After a long prodromal phase, AD manifests it-
self clinically by a progressive cognitive decline followed
by gradual personality changes [2]. Currently, there is no
proven disease-modifying treatment available [3]. Interven-
tions with current approved drugs, if started early enough,
may at best temporarily slow down the progression but
cannot impede dementia [4]. Thus, new therapeutic strat-
egies are in the focus of drug discovery programs [5, 6].
Neuropathological hallmarks of AD are extracellular amyl-
oid plaques and intracellular neurofibrillary tangles [7, 8].
Amyloid plaques are composed of beta-amyloid (Aβ) pro-
tein, processed from the beta-amyloid precursor protein
(AβPP) by initial β-secretase cleavage resulting in peptide
C99. Subsequent cleavage of C99 by the γ-secretase com-
plex results in the formation of Aβ species of different
lengths ranking from Aβ39 to Aβ43 [9]. β-Secretase, γ-
secretase, and Aβ itself were identified as pharmacological
targets [10]. Peroxisome proliferator-activated receptor
gamma (PPARγ) represents another target for AD treat-
ment [11–13]. A small pilot study that tested PPARγ agon-
ist pioglitazone in patients with mild AD accompanied
with type II diabetes exhibited cognitive and functional
improvements [14]. Another preliminary study with rosi-
glitazone also showed preserved cognition in patients with
early AD [15]. However, a large randomized clinical trial
failed to show clinical efficacy of rosiglitazone in AD. In
this trial, also no treatment difference in cognitive testing
was detected for the competitor donepezil [16].
Beside its effects on AβPP processing and Aβ-mediated
cell death, including reduced BACE1 expression and tran-
scription, decreased BACE1 promoter activity, and a clear-
ance mechanism for Aβ [17–19], PPARγ agonists provide
neuroprotection by improving mitochondrial dysfunction
in models of neurodegenerative diseases [20, 21]. As an
early event in AD pathogenesis [22, 23] mitochondrial dys-
function contributes to an impairment of the energy metab-
olism, defects in key respiratory enzyme activity/function,
accumulation/generation of mitochondrial reactive oxida-
tive species (ROS), induction of apoptosis, and altered
mitochondrial biogenesis and dynamics [24, 25]. These
observations led to the hypothesis that impaired mitochon-
drial function, associated with reduced energy metabolism
and enhanced oxidative stress as well as synaptic dysfunc-
tion, represents a common final pathway of all specific
(genetic) and nonspecific risk factors for the development
of AD [22, 26, 27]. This concept was put forward in the
“mitochondrial cascade hypothesis” first proposed more
than 10 years ago by Swerdlow et al. [28, 29]. This concept
suggests that mitochondria at least mediate or possibly even
initiate pathologic molecular cascades in AD [30].
Peroxisome proliferator-activated receptor-gamma co-
activator alpha (PGC-1α) is a nuclear factor that regu-
lates mitochondrial biogenesis in response to diverse
environmental stimuli [31]. PGC-1α has been associated
with AD [32] and PGC-1α messenger RNA expression
was reported to be significantly decreased as a function
of progression of clinical dementia in the AD brain [33].
It has been reported that PGC-1α could protect cells
against oxidative stress and reduce mitochondrial
dysfunction [32].
The pirinixic adic derivate MH84 (ethyl 2-(4,6-bis(4-(tri-
fluoromethyl)-phenethoxy)pyrimidin-2-yl-thio)hexanoate)
(Fig. 1) was developed from the optimization of a novel
structural class of dual γ-secretase/PPARγ modulators
[12, 34]. Pharmacokinetic properties of MH84 were
investigated after oral administration of a single dose
of 12 mg/kg b.w. in C57-Bl/6 mice and published
previously (Table 1) [35]. In brain tissue a constant
level of 300 to a maximum 320.64 ng/g was found
after 1.5–6 hours [35]. We recently demonstrated that
MH84 improved mitochondrial dysfunction in a cellular
model of AD [36]. In the present study, we extended the
pharmacological characterization of MH84 to 3-month-old
Thy-1 AβPPSL mice which are characterized by enhanced
AβPP processing and cerebral mitochondrial dysfunction,
representing a mouse model of early AD [37, 38].
Methods
Chemicals
Unless otherwise stated, chemicals were obtained from
Sigma-Aldrich (Taufkirchen, Germany). MH84 (ethyl
2-(4,6-bis(4-(trifluoromethyl)phenethoxy)pyrimidin-2-
yl-thio)hexanoate) was synthesized according to litera-
ture procedures [12]. Analytical NMR data of the
batch used for the current study are as follows (see
also Additional file 1: Figure S1):
1H-NMR (300.13 MHz, (CD3)2SO): δ = 0.78–0.83 (t,
3H, J = 7.1 Hz, Bu-CH3), 1.22–1.37 (m, 4H, Bu-CH2),
Fig. 1 Molecular structure of MH84 (ethyl 2-(4,6-bis(4-
(trifluoromethyl)phenethoxy)pyrimidin-2-yl-thio)hexanoate) [12]
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1.74–1.92 (m, 2H, Bu-CH2), 3.06–3.11 (t, 4H, J =
6.6 Hz, Ph-CH2), 4.27–4.30 (t, 1H, J = 7.1 Hz, S-CH),
4.48–4.53 (t, 4H, J = 6.6 Hz, Pyr-O-CH2), 5.87 (s, 1H,
Pyr-CH), 7.49–7.52 (d, 4H, J = 8.0 Hz, Ph-C2/6), 7.63–
7.66 (d, 4H, J = 8.0 Hz, Ph-C3/5), 12.82 (s/br, 1H,
COOH). 13C-NMR (75.44 MHz, (CD3)2SO): δ = 13.64
(Bu-CH3), 21.67 (Bu-CH2), 28.92 (Bu-CH2), 30.91 (Bu-
CH2), 34.16 (2C, Ph-CH2), 47.46 (S-CH), 66.54 (2C, Pyr-O-
CH2), 85.97 (Pyr-C5), 124.99 (4C, Ph-C3/5), 125.14–127.74
(2C, -CF3), 129.69 (4C, Ph-C2/6), 143.06 (2C, Ph-C1),
168.95 (Pyr-C2), 169.97 (2C, Pyr-C4/6), 172.23 (COOH).
MS (ESI): m/e = 601.4 (M–1). Anal. (C28H28F6N2O4S
(602.17)) C, H, N, S: ber, C 55.81, H 4.68, N 4.65, S
5.32; gef, C 56.10, H 4.86, N 4.40, S 5.40; Abw, C
0.29, H 0.18, N 0.25, S 0.08.
Animals and treatment
Twenty-two C57BL/6 mice at the age of 3 months bear-
ing the human Swedish (S: KM595/596NL) and London
(L: V717I) mutations in the 751 amino acid form of
human amyloid-beta precursor protein (AβPP) under
control of a murine Thy-1 promoter were randomly di-
vided into two groups of 11 Thy-1 AβPPSL mice (Thy-1
AβPPSL (control) and Thy-1 AβPPSL (MH84)) [39]. A num-
ber of 11 wild-type littermate animals were used as non-
transgenic controls. Each group consisted of six females
and five males. All animals were genotyped by tail biop-
sies and polymerase chain reaction before and after the
experiments (data not shown). Animals were housed
according to the German guidelines for animal care with
access to water and food ad libitum. They were main-
tained on a 12-h light/dark cycle. Thy-1 AβPPSL (MH84)
mice received 12 mg/kg b.w. MH84 by oral gavage once a
day for 21 days. MH84 was diluted in polyethylene glycol
400 (PEG400). Control groups received an equal amount
of PEG400. Health was assessed daily and PEG400 had no
adverse effects. The mice were sacrificed by decapitation
after cervical dislocation and the brains were quickly dis-
sected on ice after removal of the cerebellum, the brain
stem, and the olfactory bulb. All experiments were
carried out by individuals with appropriate training
and experience according to the requirements of the
Federation of European Laboratory Animal Science
Associations and the European Communities Council
Directive (Directive 2010/63/EU). Experiments were
approved by the regional authority (Regierungspraesi-
dum Darmstadt; #V54-19 c 20/15-FU_K_5003).
Preparation of isolated brain mitochondria
Brain mitochondria were isolated from one hemisphere
as reported previously [40]. Briefly, the cerebrum was
homogenized using a potter equipped with a Teflon® pis-
til in 2 ml mitochondrial respiration medium (MiR05)
containing a protease inhibitor cocktail (PI, complete;
Roche, Mannheim, Germany). The resulting homogenate
was centrifuged to remove the nuclei and other cell deb-
ris (1400 × g, 7 min, 4 °C). The low-speed centrifugation
step was repeated once (for 3 min) with the supernatant
followed by a high-speed centrifugation step (10.000 × g,
5 min, 4 °C) to collect a pellet enriched in mitochondria.
This pellet was resuspended in 1 ml ice-cold MiR05 + PI
and centrifuged (1400 × g, 3 min, 4 °C). The supernatant
was centrifuged once again at high speed (10.000 × g,
5 min, 4 °C) to obtain the mitochondrial fraction. The
resulting pellet was then dissolved in 250 μl MiR05 + PI.
The obtained solution of isolated mitochondria was then
used for high-resolution respirometry (80 μl). The
remaining solution was immediately frozen in liquid
nitrogen for citrate synthase (CS) activity (120 μl) and
protein determinations (50 μl) and stored at –80 °C.
High-resolution respirometry
Mitochondrial respiration was analyzed as reported pre-
viously [40]. Briefly, 80 μl of isolated mitochondria in
MiR05 were injected into a chamber of the Oxygraph-
2 k at 37 °C (Oroboros, Innsbruck, Austria), and a com-
plex protocol (developed by Erich Gnaiger, Innsbruck,
Austria) containing different substrates, uncouplers, and
inhibitors was carried out [41]. The capacity of oxidative
phosphorylation (OXPHOS) was determined with com-
plex I-related substrates (CIOXPHOS) pyruvate (5 mM),
malate (2 mM), and adenosine 5′-diphosphate (ADP)
(2 mM) followed by addition of succinate (10 mM, CI +
IIOXPHOS). Mitochondrial integrity was examined via
addition of cytochrome c (10 μM). Subsequently, oligomy-
cin (2 μg/ml) was added to reveal leak respiration (leak
omy). The maximum capacity of the electron transfer sys-
tem (ETS) was achieved by titration of carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone (FCCP). Complex
II respiration in the noncoupled state (CIIETS) was mea-
sured after adding rotenone (0.5 μM) into the chambers.
Residual oxygen consumption (ROX) was determined
after inhibition of complex III by addition of antimycin A
Table 1 Pharmacokinetic parameters of MH84
Parameter Value
Cmax (μg/g plasma) 10.90
Tmax (h) 3.00




Plasma levels of MH84 were determined using HPCL after single oral gavage
of 12 mg/kg MH84. The following pharmacokinetic parameters were adopted
from our previous publication (for details, please refer to Pellowska et al. [35]):
Cmax, maximum concentration; Tmax, time to reach Cmax; AUC48h, area under the
curve until 48 h; T1/2, half-life time; CL, clearance; Vd, volume of distribution
MH84 ethyl 2-(4,6-bis(4-(trifluoromethyl)phenethoxy)pyrimidin-2-yl-thio)hexanoate
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(2.5 μM) and was subtracted from all respiratory parame-
ters. Cyclooxygenase activity (CIVETS) was measured after
by applying 0.5 mM tetramethylphenylenediamine
(TMPD) as an artificial substrate of CIV and 2 mM ascor-
bate to keep TMPD in the reduced state. The autoxidation
rate was determined after the addition of sodium azide
(≥100 mM). For data analysis, DatLab 5.1.1.7 software
(Oroboros) was used. Data of mitochondrial respiration
were normalized to CS activity.
Preparation of dissociated brain cells for in-vitro studies
Dissociated brain cells (DBC) were isolated from one
hemisphere as reported previously [37, 40]. Briefly, after
preparation, DBC were resuspended in 4.5 ml DMEM
without supplements. The suspension was seeded in
250-μl aliquots into a 24-well plate with 12 replicates
(for measurement of mitochondrial membrane potential)
or in 50-μl aliquots into a 96-well plate with 12 repli-
cates (for measurement of ATP level). Afterward the
cells were maintained for 3 h at 37 °C in a humidified in-
cubator, gassed with 5% CO2. A 1-ml aliquot of the
remaining cell suspension was collected and immediately
frozen at –80 °C for protein determination.
Determination of mitochondrial membrane potential
The potential of the inner mitochondrial membrane
(MMP) was determined in DBC as described previously
using the cell-permeable fluorescent dye rhodamine 123
(R123) with a VICTOR™ X3 2020 Multilabel Counter
(Perkin Elmer, Rodgau, Germany) [40].
Determination of ATP levels
ATP levels were determined in DBC using the ViaLight®
Plus bioluminescence assay according to the manufac-
turer’s instructions (Lonza, Walkersville, USA) with a
VICTOR™ X3 Multilabel Counter (Perkin Elmer), as de-
scribed previously [37, 40].
Citrate synthase activity
CS activity was determined in isolated mitochondria as
described previously [40]. A frozen subsample of the
isolated mitochondria dissolved in MiR05 was thawed on
ice. A reaction medium containing 100 μl of 0.1 mM 5,5′-
dithiobis-(2-nitrobenzoic acid) (DTNB), 25 μl of 10%
Triton X-100, 50 μl of 10 mM oxaloacetate, 25 μl of
12.2 mM acetyl coenzyme A, and 790 μl purified water
was mixed and preheated at 30 °C for 5 min. Subse-
quently, 10 μl of the isolated mitochondria was added to
the reaction medium and transferred into a 10-mm quartz
cuvette (Hellma® Analytics, Muellheim, Germany). CS ac-
tivity was assessed at 412 nm using a GENESYS 5 spectro-
photometer (Spectronic via Thermo Fisher Scientific,
Waltham, MA, USA) and normalized to protein content.
Measurements were performed in duplicate.
Cell culture
Human embryonic kidney (HEK) 293 cells containing hu-
man wild-type AβPP (HEK293AβPPwt) and HEK293AβPPsw
cells transfected with DNA constructs harboring human
mutant AβPP (AβPPsw, KM670/671NL) gene were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum,
50 units/ml penicillin, 50 μg/ml streptomycin, and 400 μg/
ml Geniticin (G418). Both cell lines were maintained in a
humified incubator, gassed with 5% CO2 at 37 °C as
described previously [36]. The HEK293AβPPwt cell line was
a kind gift received from Prof. Christian Haass, Munich,
Germany.
MitoTracker Green
MitoTracker Green (MTG) measurements were per-
formed as described previously [42]. Briefly, 2 days before
the measurement 100,000 cells/well of HEK293AβPPwt cells
and HEK293AβPPsw cells were seeded into a 24-well plate.
On the next day cell medium was incubated for 24 h with
0.1 μM MH84. For solvent control DMSO (0.05%) was
used. Afterward the cells were washed with 500 μl Hank’s
Balanced Salt Solution buffer (HBSS) (pH 7.4, 37 °C sup-
plemented with Mg2+,Ca2+ and HEPES) and spiked with
1 μM MTG (Invitrogen, Camarillo, USA) and incubated
for 60 min. After adding fresh HBSS buffer to the cells,
fluorescence was measured at an excitation wavelength of
490 nm and an emission wavelength of 516 nm in a VIC-
TOR™ X3 Multilabel Counter (Perkin Elmer). When
comparing HEK293AβPPwt cells and HEK293AβPPsw cells,
fluorescence values were normalized to protein content.
Determination of soluble Aβ
The content of soluble Aβ1–40 and Aβ1–42 in supernatants
was detected by specific solid phase sandwich enzyme-
linked immunosorbent assays (ELISA; Life Technologies,
Carlsbad, CA, USA) following the instructions of the sup-
plier. Brain material was homogenized in 10 times the
amount of phosphate-buffered saline containing a prote-
ase inhibitor cocktail. After homogenization, samples were
centrifuged (15,000 × g, 30 min, 4 °C) and the superna-
tants were transferred to a fresh reaction vessel and stored
at –80 °C prior to analysis. Total protein content was





B2M 5′-GGC CTG TAT GCT ATC CAG AA-3′
5′-GAA AGA CCA GTC CTT GCT GA-3′
NM_009735.2 198
PGK1 5′-GCA GAT TGT TTG GAA TGG TC-3′
5′-TGC TCA CAT GGC TGA CTTT TA-3′
NM_008828.2 185
BACE1 Confidential NC_000075.6 65
PGC1α 5′-TGT CAC CAC CGA AAT CCT-3′
5′-CCT GGG GAC CTT GAT CTT-3′
NM_008904.2 124
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determined using a Pierce™ BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL, USA).
Western blot analysis
Western blot analysis was carried out in brain tissue
homogenates as reported previously [36]. Briefly, brain
samples were homogenized in lysis buffer. Total protein
content was determined using a Pierce™ BCA Protein Assay
Kit (Thermo Scientific). Band analysis was performed using
ChemiDoc XRS system (BioRad, Munich, Germany). The
following antibodies were used: full-length AβPP (fl-AβPP)
and C-terminal fragments (CTFs) were detected using
AβPP C-Terminal Fragment (C1/6.1) antibody (SIG-39152;
Covance, Princeton, NJ, USA). Detection of respiratory
system complexes was carried out by MitoProfile® Total
OXPHOS Rodent WB Antibody Cocktail (ab110413;
abcam, Cambridge, UK). As primary antibody for synaptic
markers, Anti-BDNF (ab72439; abcam), Anti-GAP43
Fig. 2 Brain levels of full-length amyloid precursor protein (a, b fl-AβPP) and its α-secretase and β-secretase cleavage products C83 and C99,
respectively (b, c, d) detected using western blot techniques. Data represent means ± SEM from eight experiments; one-way ANOVA with Tukey’s
multiple comparison post test (*p < 0.05, **p < 0.01, ***p < 0.001 against wild-type(control);
+++p < 0.001 against Thy-1 AβPPSL (control)). Levels of
soluble human β-amyloid peptides (e Aβ40 and f Aβ42) were determined using ELISA. Data represent means ± SEM. N = 11 (six females, five
males); Student’s unpaired t test (**p < 0.01 against Thy-1 AβPPSL (control)). AβPP beta-amyloid precursor protein, Aβ amyloid-beta
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(ab12274; abcam), and Anti-synaptophysin (ab32127;
abcam) were used. To detect protein expression of PGC-
1α in the brain, Anti-PGC-1α antibody (ab106814; abcam)
was used. Anti-tubulin antibody (ab6160; abcam) and Anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) anti-
body (MAB374; Merck Millipore, Darmstadt, Germany)
were used to verify equal protein loading.
Quantitative real-time PCR
qRT-PCR measurements were carried out as described
previously [42]. Briefly, total RNA was isolated from fro-
zen brain tissues using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions. Maximum yield of RNA was obtained using
20 mg/ml Proteinase K (Carl Roth, Karlsruhe, Germany).
RNA was quantified by measuring the absorbance at
260 nm using a NanoDrop™ 2000c spectrophotometer
(Thermo Fisher Scientific). Purity of RNA was assessed
by the ratio of absorbance at 260 nm and 280 nm. First-
strand cDNA was synthesized from 50 ng total RNA
using the iScript cDNA synthesis kit (BioRad) according
to the manufacturer’s instructions. Real-time PCR was
performed using SYBR Green technology on a CFX96
Touch™ Real-Time PCR Detection System (BioRad).
Target-specific primer pair reference genes PGK1 and B2M
were purchased from biomol (Hamburg, Germany). Beta-
site AβPP cleaving enzyme (BACE1) primer pairs were pur-
chased from Bio-Rad Laboratories. PGC-1α primer pairs
were designed by biomers.net (Ulm, Germany) (Table 2).
Prior optimization was conducted for each set of
primers, which consisted of determining optimal primer
concentration and template concentration and verifying
the efficiency of the amplification. To confirm the
specificity of the amplification, the PCR product was
subjected to melting curve analysis and agarose gel elec-
trophoresis. PCR amplification was performed in dupli-
cate in a total reaction volume of 10 μl. The reaction
mix consisted of 2 μl template, 5 μl iTaq™ Universal
SYBR® Green Supermix, and forward and reverse
primers at the following concentrations: 50 nM (PGC-
1α), 200 nM (BACE1), or 400 nM (PGK1, B2M). After a
3-min activation of Taq polymerase, amplification was
allowed to proceed for 46 cycles. Each cycle consisted of
denaturation at 95 °C for 10 s, annealing at 58 °C for
45 s, and extension at 72 °C for 29 s. BACE1 mRNA ex-
pression was performed in a two-step PCR amplification.
After a 2-min activation of Taq polymerase, amplification
was allowed to proceed for 40 cycles. Each cycle consisted
of denaturation at 95 °C for 5 s and annealing and exten-
sion at 60 °C for 30 s. The one-cycle melting curve con-
sisted of heating from 65 to 95 °C by 0.5 °C steps, with 5-s
hold per step. Results were normalized to PGK1 and B2M
as reference genes which are stably expressed in mouse
brain [43]. Results were analyzed using the 2–ΔΔCq
method with target-specific amplification efficiency.
Statistical analysis
All data are presented as means ± SEM. For statistical ana-
lysis GraphPad Prism 5.03 software (GraphPad Software,
Inc., La Jolla, CA, USA) was used. For the examination of
statistical significant differences between two groups a
two-sided, unpaired Student’s t test and for multiple
comparisons a one-way ANOVA with Tukey’s multiple
comparison post test or a two-way ANOVA followed by
Fig. 3 Brain levels of PGC-1α protein (a) and mRNA (b). Representative western blot assays are included in lower part of a. Band of PGC-1α was located
in second place at 100 kDa. Tubulin used as loading control. Expression levels of mRNA were normalized to PGK1 and B2M mRNA expression. Citrate
synthase (CS) activity as a marker of mitochondrial content was determined in isolated brain mitochondria using a photometrical assay (c). Animals
belonged to three different study groups (wild-type(control), Thy-1 AβPPSL (control), and treatment group Thy-1 AβPPSL (MH84)). Data represent means ± SEM.
N = 11 (six females, five males); one-way ANOVA with Tukey’s multiple comparison post test (*p < 0.05, ***p < 0.001 against wild-type(control);
++p < 0.01,
+p < 0.05 against Thy-1 AβPPSL (control)). PGC-1α peroxisome proliferator-activated receptor-γ coactivator alpha, AβPP beta-amyloid precursor protein
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Bonferroni post test was performed. p < 0.05, p < 0.01, and
p < 0.001 were considered statistically significant.
Results
MH84 decreased β-secretase cleavage and Aβ40 levels
Protein levels of full-length AβPP (fl-AβPP) were in-
creased in brains of Thy-1 AβPPSL mice (Fig. 2a, b).
Elevated protein levels of the β-secretase cleavage prod-
ucts C99 and C83 were also detected (Fig. 2b–d). Ap-
proximately 68 and 18 pg/mg of human Aβ40 and Aβ42
were determined in brain tissues of Thy-1 AβPPSL mice,
respectively (Fig. 2e, f ). Levels of soluble human Aβ40 or
Aβ42 were not detectable in wild-type control mice
(data not shown). Treatment with MH84 significantly
Fig. 4 Western blot analysis of mitochondrial respiration chain complexes (a CI, b CII, c CIII, d CIV, e CV) in brain homogenate from wild-
type(control), Thy-1 AβPPSL (control), and MH84-treated Thy-1 AβPPSL mice. Representative western blots included in lower part of the figure (f).
GAPDH was used as loading control. Data represent means ± SEM. N = 11 (six females, five males); one-way ANOVA with Tukey’s multiple
comparison post test (***p < 0.001, **p < 0.01, *p < 0.05 against wild-type(control);
+++p < 0.001, ++p < 0.01 against Thy-1 AβPPSL (control)). CI complex I
(NADH reductase), CII complex II (succinate dehydrogenase), CIII complex III (cytochrome-c reductase), CIV complex IV (cytochrome-c oxidase), CV
complex V (F1/F0-ATPase), AβPP beta-amyloid precursor protein
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decreased the β-secretase cleavage product C99 and
levels of soluble human Aβ40 in brain homogenates of
Thy-1 AβPPSL mice (Fig. 2c, e). Expression of the β-site
of APP cleaving enzyme (BACE1) significantly increased
in Thy-1 AβPPSL mice and administration of MH84 nu-
merically but not significantly reduced BCAE1 mRNA
levels (Additional file 2: Figure S2).
MH84 enhanced PGC-1α expression, mitochondrial mass,
and BDNF levels
Protein and mRNA levels of PGC-1α were significantly
decreased in the brain of Thy-1 AβPPSL mice (Fig. 3a, b).
Since PGC-1α represents one of the most important nu-
clear factors for the induction of mitogenesis [34], this
finding might indicate a reduced mitochondrial mass in
brains of Thy-1 AβPPSL mice. Accordingly, CS activity
representing a robust mitochondrial mass marker [44]
was also significantly decreased (Fig. 3c). Decreased pro-
tein levels of mitochondrial respiration complexes (CII–
CV) further indicate a reduced mitochondrial mass in
brains of Thy-1 AβPPSL mice (Fig. 4a–f ). MH84 reversed
protein and mRNA levels of PGC-1α as well as of CS ac-
tivity (Fig. 3a–c). Moreover, MH84 significantly enhanced
protein levels of CIV and CV (Fig. 4d, e). Moreover,
MH84 reversed the fluorescence of the mitochondrial
mass marker MitoTracker Green (MTG) in HEK293-
AβPPsw cells, which further indicated that MH84 en-
hanced mitochondrial content (Fig. 5). HEK293-AβPPsw
cells represent a cellular AD model characterized by
elevated Aβ levels and mitochondrial dysfunction
[36, 45, 46].
A recent report related reduced PGC-1α levels to re-
duced expression of brain-derived neurotrophic factor
(BDNF) [47]. Western blot analysis show significantly
decreased brain levels of BDNF (Additional file 2: Figure
S2). The synaptic marker protein growth associated pro-
tein 43 (GAP43) was also significantly reduced in brain
samples of Thy-1 APPSL mice, but not of synaptophysin
(Additional file 2: Figure S2). MH84 administration
increased BDNF protein levels but had no effects on the
synaptic marker proteins GAP43 and synaptophysin
(Additional file 3: Figure S3).
MH84 reversed mitochondrial dysfunction
The complexes of the mitochondrial respiration chain
(complex I, NADH reductase (CI); complex II, succinate
dehydrogenase (CII); complex III, cytochrome-c reduc-
tase (CIII); complex IV, cytochrome-c oxidase (CIV))
build up a proton gradient at the inner mitochondrial
membrane. The resulting membrane potential (MMP)
finally represents the driving force for complex V of the
mitochondrial respiration chain (F1/F0-ATPase (CV))
that produces ATP. Respiration of CIV of the mitochon-
drial respiration chain was significantly decreased in
mitochondria isolated from brains of Thy-1 AβPPSL
mice (Fig. 6a). Consequently, MMP and ATP levels were
significantly decreased in DBC isolated from Thy-1
AβPPSL mice (Fig. 6b, c). All three parameters were re-
versed after MH84 treatment (Fig. 6a–c).
Discussion
In this study, the effects of MH84 on mitochondrial dys-
function were investigated in 3-month-old transgenic
Thy-1 AβPPSL mice representing a model of early AD
[37]. Since these mice develop typical Aβ plaques at the
age of 6 months [39], we focused on soluble Aβ levels
and confirm moderately elevated cerebral content of Aβ
at an age of 3 months [39]. Moreover, levels of fl-AβPP
and C99 were enhanced in brains of these mice as well.
There is evidence that accumulation of Aβ, fl-AβPP, and
C99, which are able to enter mitochondria and interact
with mitochondrial proteins, might result in impaired mito-
chondrial function and energy metabolism [27, 48–52].
However, mitochondrial dysfunction might also be a result
of lower levels of PGC-1α [32, 53]. There is convincing
evidence for a link between PGC-1α and AD [32, 47], and
numerous studies demonstrated that the pharmacological
targeting of particular nuclear receptors is beneficial in
mouse models of AD (reviewed in [13]). Decreased levels of
PGC-1α have been reported in postmortem brain tissue of
Fig. 5 MitoTracker Green (MTG) fluorescence as a marker for
mitochondrial content measured in HEK293AβPPwt and HEK293AβPPsw
cells. Data represent means ± SEM from 12 independent
experiments; one-way ANOVA with Tukey’s multiple comparison
post test (*p < 0.05 against HEK293AβPPwt (control);
++p < 0.01 against
HEK293AβPPsw (control)). APP amyloid precursor protein
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AD patients [33] and in a AβPPswe/PS1de9 mouse model
of AD [54]. PGC-1α protein and mRNA levels were also
found to be significantly decreased in the present study.
PGC-1α has been characterized as one of the main regula-
tors of PPARγ and as an essential initiator for mitochon-
drial biogenesis and respiration [55, 56]. Thus, decreased
PGC-1α levels might play a role for impaired mitochondrial
biogenesis [57] and mitochondrial dysfunction [37]. Ac-
cordingly, we determined the activity of the mitochondrial
marker enzyme CS, which has been reported as one of the
best markers of mitochondrial mass [58]. In our study, CS
activity was significantly reduced in mitochondria isolated
from brains of Thy-1 AβPPSL mice, indicating reduced
mitochondrial mass. This finding is in agreement with
reduced PGC-1α levels in brain tissue samples isolated
from these mice. However, Hauptmann et al. [37] de-
tected no differences in the mitochondrial content in
brains of Thy-1 AβPPSL mice using MitoTracker Green
fluorescence and PCR. On the other hand, reduced
complex IV activity, MMP, and ATP levels are in
accordance with this earlier publication [37] and other
reports on mouse models of AD [59–61].
Mice were treated for 21 days with 12 mg/kg body
weight (b.w.) MH84 using oral gavage. Pharmacokinetic
properties of MH84 were investigated previously and we
reported a maximum brain concentration of 320.64 ng/g
[35]. MH84 is a small molecule that has been characterized
as a dual PPARγ agonist and γ-secretase modulator in vitro
Fig. 6 Analysis of mitochondrial respiration of isolated brain mitochondria (a) performed using an Oxygraph-2 k system. Animals belonged to
three different study groups (wild-type(control), Thy-1 AβPPSL (control), and treatment group Thy-1 AβPPSL (MH84)). To analyze mitochondrial function
different substrates, uncouplers and inhibitors were added; for details please refer to Methods. Data represent means ± SEM from 10 experiments;
two-way ANOVA with Bonferroni post test (*p < 0.05 against wild-type(control);
+++p < 0.001 against Thy-1 AβPPSL (control)). Basal mitochondrial
membrane potential (MMP; R123 fluorescence) (b) and ATP levels (c) of mitochondria measured in dissociated brain cells. MMP determined using
R123 as fluorescence dye. ATP levels determined using a bioluminescence assay. Data represent means ± SEM. N = 11 (six females, five males);
one-way ANOVA with Tukey’s multiple comparison post test (*p < 0.05 against wild-type(control);
+p < 0.05, ++p < 0.01 against Thy-1 AβPPSL (control)).
CI complex I (NADH reductase, CII complex II (succinate dehydrogenase), CIV complex IV (cytochrome-c oxidase), ETS electron transfer system,
AβPP beta-amyloid precursor protein
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[12, 34, 62]. However, our in-vivo data indicated modula-
tion of β-secretase rather than γ-secretase: Treatment with
MH84 significantly decreased the β-secretase cleavage
product C99 and levels of soluble human Aβ40 in brain
homogenates of Thy-1 AβPPSL mice.
The present study also shows that MH84 reversed
mitochondrial dysfunction and PGC-1α levels, de-
creased β-secretase processing of AβPP, and reduced
levels of soluble Aβ40 in brains of transgenic Thy-1
AβPPSL mice. These findings are in line with data for a
cellular model of AD that we have been reported re-
cently [36]. PGC-1α regulates a large set of mitochon-
drial genes as an essential initiator for mitochondrial
biogenesis and respiration [55, 56]. Thus, increased CS
activity and OXPHOS protein levels indicate that
MH84 enhanced biogenesis of mitochondria by a PGC-
1α-dependent mechanism and thereby compensates for
mitochondrial dysfunction in brains of Thy-1 AβPPSL
mice. Enhanced MitoTracker Green (MTG) fluores-
cence after incubation of HEK-AβPPsw cells with
MH84 further supports this hypothesis. MTG accumu-
lates in mitochondria independently of the mitochon-
drial membrane potential and thus represents another
suitable marker for the determination of mitochondrial
content [63]. Katsouri et al. [19, 64] showed that PGC-
1α reduces Aβ generation through a PPARγ-dependent
mechanism and demonstrated recently that PGC-1α
transfer reduces neuronal loss and Aβ generation by
reducing β-secretase in an AD mouse model. Thus,
PGC-1α might also be responsible for the β-secretase-
related reduction of Aβ40 levels after treatment with
MH84 in brains of Thy1-AβPPSL. However, in our
study MH84 did not reverse enhanced BACE1 mRNA
levels in brains of Thy1-AβPPSL mice. On the other
site, PGC-1α overexpression was reported to exacerbate
Aβ and tau deposition in another transgenic mouse
model of AD [65].
BDNF represents one of the most widely distributed
and extensively studied neurotrophins in the mammalian
brain. Its functions include developmental processes,
regulation of synaptogenesis, and neuroprotection [66].
Decreased BDNF levels have been determined in
brains of AD patients [67] and reduced expression of
BDNF has been related to reduced PGC-1α levels in a
mouse model of AD [47]. We report a significant
downregulation of BDNF levels in brains of in brains
of Thy-1 AβPPSL mice, which was reversed after treat-
ment with MH84. Thus, effects of MH84 might at
least partly be related to enhanced BDNF expression
although synaptic marker proteins were not changed.
Conclusion
MH84 represents a dual γ-secretase/PPARγ modulator
that improves mitochondrial dysfunction by enhancing
mitochondrial dysfunction via a PGC-1α-dependent
mechanism. Thus, MH84 seems to be a new promising
therapeutic agent with approved in-vivo activity for the
treatment of AD that could help to modify the disease
progression in early stages.
Additional files
Additional file 1: Figure S1. Representative NMR spectra of MH84 used
for the current study. For analytical details please refer to [12]. (PDF 429 kb)
Additional file 2: Figure S2. Brain levels of the β-site of APP cleaving
enzyme (BACE-1) mRNA. Expression levels of mRNA were normalized to
PGK1 and B2M mRNA expression. Animals belonged to three different
study groups (wild-type(control), Thy-1 AβPPSL (control), and treatment group
Thy-1 AβPPSL (MH84)). Data represent means ± SEM. N = 11 (six females,
five males); one-way ANOVA with Tukey’s multiple comparison post test
(**p < 0.01, against wild-type(control)). (TIFF 562 kb)
Additional file 3: Figure S3. Western blot analysis of A brain-derived
neurotrophic factor (BDNF), B Growth associated protein 43 (GAP43), and C
synaptophysin in brain homogenate isolated from wild-type mice (control),
Thy-1 AβPPSL (control), and MH-84-treated Thy-1 AβPPSL (MH84) mice. Tubulin
(A, C) and GAPDH (B) were used as loading controls. Data represent
means ± SEM. N = 11 (six females, five males); one-way ANOVA with
Tukey’s multiple comparison post test (***p < 0.001, **p < 0.01, against
wild-type(control);
+p < 0.05 against Thy-1 AβPPSL (control)). (TIFF 12802 kb)
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